Quantcast

Latest Medical statistics Stories

2014-08-26 08:31:09

PRINCETON, N.J., Aug. 26, 2014 /PRNewswire/ -- WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has appointed David Borasky as vice president of quality management for the Copernicus Group Independent Review Board. http://photos.prnewswire.com/prnvar/20140422/77410 "David brings a wealth of international experience to the WCG team," said WCG Chairman & Chief Executive Officer Donald...

2014-08-13 08:28:42

Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry...

2014-08-12 08:31:39

CLEVELAND, Aug. 12, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics, Inc., a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it successfully completed the Phase I arm of the RETRO-HF clinical trial, and fully enrolled the Phase II arm that is evaluating the safety and preliminary clinical efficacy for retrograde infusion of JVS-100 in patients with heart failure....

2014-08-11 08:29:14

Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, following a 9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing...

2014-08-06 23:02:13

Published since 2006, the Orange Paper gives detailed snapshot of clinical trials in Russia. Moscow, Russia (PRWEB) August 06, 2014 Synergy Research Group has released its Q2, 2014 Orange Paper. Published since 2006, the Synergy Orange Paper gives an unbiased and detailed view of the state of clinical trials in Russia. The report, which is issued quarterly, gives a strategic overview and drills down into additional data, such as the number of trials, top companies that initiated studies...

2014-07-21 12:25:16

ALBANY, New York, July 21, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "E-Clinical Solution Software Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global microfluidic device market was valued at USD 3,005 million in 2014 and is expected to grow at a CAGR of 13.8% from 2014 to 2020, to reach an estimated value of USD 6,515.3 million in 2020. Browse the full E-Clinical...

2014-06-23 04:20:31

LONDON, June 23, 2014 /PRNewswire/ -- Highlights: - Creation of an international CRO with complete service offering from Phase I to Phase IV post-authorisation studies - Appointment of a highly experienced Board, including Professor Trevor Jones CBE, Chairman, Ronald Openshaw, Chief Executive Officer and Professor Sir Christopher Evans, Non-Executive Director - Completed with GBP12.5m of funds raised from Welsh...

2014-06-16 12:29:16

Aspire IRB and Midlands IRB become part of the WCG family, further expanding its geographic and program reach PRINCETON, N.J., June 16, 2014 /PRNewswire/ -- The WIRB-Copernicus Group ("WCG"), the world's largest provider of regulatory and ethical review services for clinical research, announced today that two independent review boards (IRBs) - Aspire IRB and Midlands IRB - have joined the Group. Located near San Diego, CA and Kansas City, MO, respectively, these companies expand...

2014-06-16 08:29:45

PHILADELPHIA, June 16, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") is launching two new global initiatives enabled by broad participation and collaboration across the global research and development (R&D) community: develop a position on the best and most efficient methods for redacting privacy information found in clinical study reports and an approach for the anonymization of patient level data shared with the broader healthcare community; and develop a...

2014-06-04 08:30:14

SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce the distribution of a letter from Hojabr Alimi, the Company's Chairman, Chief Executive Officer and Chief Science Officer, to its stockholders on Form 8-K on June 3, 2014. A download of the full PDF of this...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related